Guardant data another step forward for tissue-agnostic diagnostics

Guardant Health's NGS-based liquid biopsy test can identify microsatellite instability in cancer patients, offering a less invasive option for screening patients who could benefit from tissue-agnostic immunotherapies. The data were published in a Clinical Cancer Research paper Monday.

Microsatellite instability (MSI) is the result of defective DNA damage repair (dMMR) and has been identified as a biomarker of response to checkpoint inhibitors. ...